The ruthenium complex cis-(dichloro)tetrammineruthenium(III) chloride induces apoptosis and damages DNA in murine sarcoma 180 cells.
Ruthenium (III) complexes are increasingly attracting the interest of researchers due to their promising pharmacological properties. Recently, we reported that the cis-(dichloro)tetrammineruthenium (III) chloride compound has cytotoxic effects on murine sarcoma 180 (S-180) cells. In an effort to understand the mechanism responsible for their cytotoxicity, study we investigated the genotoxicity, cell cycle distribution and induction of apoptosis caused by cis- (dichloro) tetrammineruthenium (III) chloride in S-180 tumour cells. cis-(dichloro) tetrammineruthenium (III) chloride treatment induced significant DNA damage in S-180 cells, as detected by the alkaline comet assay. In the cell cycle analysis, cis-(dichloro) tetrammineruthenium (III) chloride caused an increase in the number of cells in G1 phase, accompanied by a decrease in the S and G2 phases after 24 h of treatment. In contrast, the cell cycle distribution of S-180 cells treated with cis-(dichloro) tetrammineruthenium (III) chloride for 48 h showed a concentration-dependent increase in the sub-G1 phase (indicating apoptosis), with a corresponding decrease in cells in the G1, S and G2 phases. In addition, cis-(dichloro) tetrammineruthenium(III) chloride treatment induced apoptosis in a time-dependent manner,as observed by the increased numbers of annexin V-positive cells. Taken together, these findings strongly demonstrate that DNA damage, cell cycle changes and apoptosis may correlate with the cytotoxic effects of cis-(dichloro) tetrammineruthenium (III) chloride on S-180 cells.
de Lima
Aliny Pereira
AP
Laboratorio de Genetica Molecular e Citogenetica, Instituto de Ciencias Biologicas, Universidade Federal de Goias - UFG, Goiania, Goias, Brazil.
Pereira
Flavia de Castro
Fde C
Vilanova-Costa
Cesar Augusto Sam Tiago
CA
Ribeiro
Alessandra de Santana Braga Barbosa
Ade S
Pavanin
Luiz Alfredo
LA
Dos Santos
Wagner Batista
WB
Silveira-Lacerda
Elisângela de Paula
Ede P
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D004249:DNA Damage; D004353:Drug Evaluation, Preclinical; D051379:Mice; D009942:Organometallic Compounds / Q000494:pharmacology*; D012428:Ruthenium / Q000494:pharmacology*; D017975:Ruthenium Compounds / Q000494:pharmacology
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; D012428:Ruthenium
Dalton Trans. 2008 Jan 14;(2):183-94
18097483
Drug Discov Today. 2009 May;14(9-10):500-8
19429510
Clin Cancer Res. 2004 Jun 1;10(11):3717-27
15173078
Mutat Res. 1995 Feb;339(1):37-59
7877644
J Inorg Biochem. 2001 Jan 15;83(2-3):139-49
11237253
Nat Rev Cancer. 2005 Nov;5(11):876-85
16239906
Gen Pharmacol. 1999 May;32(5):525-40
10382854
Cancer Lett. 2005 Aug 26;226(2):115-21
16039951
Biol Trace Elem Res. 2010 Jun;135(1-3):98-111
19727575
Cancer. 1994 Apr 15;73(8):2013-26
8156506
J Pharmacol Exp Ther. 2005 Dec;315(3):1403-11
16169939
J Inorg Biochem. 2006 Nov;100(11):1834-41
16959320
JAMA. 1998 Jan 28;279(4):300-7
9450715
Drug Resist Updat. 2006 Jun;9(3):111-22
16790363
Exp Cell Res. 2000 Apr 10;256(1):42-9
10739650
Chem Biol Interact. 2007 Apr 25;167(2):116-24
17368594
J Cancer Res Clin Oncol. 2005 Feb;131(2):101-10
15503135
J Inorg Biochem. 2006 May;100(5-6):891-904
16603249
Arch Biochem Biophys. 2000 Apr 1;376(1):156-62
10729201
Cell. 2004 Jan 23;116(2):205-19
14744432
Exp Cell Res. 1988 Mar;175(1):184-91
3345800
Biol Trace Elem Res. 2009 Sep;130(3):249-61
19214395
Carcinogenesis. 2000 Mar;21(3):485-95
10688869
Trends Cell Biol. 2001 Dec;11(12):526-34
11719060
Chem Biol Interact. 1998 May 1;113(1):51-64
9630847
Curr Med Chem. 2006;13(9):1085-107
16611086